Rebleeding rate and the need for blood transfusion in patients with upper gastrointestinal tumor bleeding  are higher  than in patients with peptic ulcer bleeding

2016 ◽  
Author(s):  
Dominik Kralj
Keyword(s):  
Peptic Ulcer ◽  
Blood Transfusion ◽  
Ulcer Bleeding ◽  
Gastrointestinal Tumor ◽  
Peptic Ulcer Bleeding ◽  
Rebleeding Rate ◽  
Tumor Bleeding ◽  
Upper Gastrointestinal

scholarly journals Clinical Outcomes of the Marginal Ulcer Bleeding after Gastrectomy: As Compared to the Peptic Ulcer Bleeding with Nonoperated Stomach

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Woo Chul Chung ◽  
Eun Jung Jeon ◽  
Kang-Moon Lee ◽  
Chang Nyol Paik ◽  
You Suk Oh ◽  
...  
Keyword(s):  
Peptic Ulcer ◽  
Clinical Outcomes ◽  
Marginal Ulcer ◽  
Ulcer Bleeding ◽  
Consecutive Series ◽  
Peptic Ulcer Bleeding ◽  
Positive Rate ◽  
Rebleeding Rate ◽  
H Pylori ◽  
Upper Gastrointestinal

Background. Marginal ulcer is a well-known complication after gastrectomy. Its bleeding can be severe, but the severity has rarely been reported. We aim to evaluate the clinical outcomes of marginal ulcer bleeding (MUB) as compared to peptic ulcer bleeding (PUB) with nonoperated stomach.Methods. A consecutive series of patients who had nonvariceal upper gastrointestinal bleeding and admitted to the hospital between 2005 and 2011 were retrospectively analyzed. A total of 530 patients were enrolled in this study, and we compared the clinical characteristics between 70 patients with MUB and 460 patients with PUB.Results. Patients with MUB were older (mean age:62.86±10.59years versus53.33±16.68years,P=0.01). The initial hemoglobin was lower (8.16±3.05 g/dL versus9.38±2.49 g/dL,P=0.01), and the duration of admission was longer in MUB (7.14±4.10days versus5.90±2.97days,P=0.03). After initial hemostasis, the rebleeding rate during admission was higher (16.2% versus 6.5%,P=0.01) in MUB. However, the mortality rate did not differ statistically between MUB and PUB groups.Helicobacter pylori-positive rate with MUB was lower than that of PUB (19.4% versus 54.4%,P=0.01).Conclusions. Clinically, MUB after gastrectomy is more severe than PUB with nonoperated stomach. Infection withH. pylorimight not appear to play an important role in MUB after gastrectomy.

Will Helicobacter Pylori Affect Short-Term Rebleeding Rate in Peptic Ulcer Bleeding Patients After Successful Endoscopic Therapy?

1999 ◽  
Vol 94 (11) ◽  
pp. 3184-3188 ◽  
Author(s):  
Hwai-Jeng Lin ◽  
Guan-Ying Tseng ◽  
Yu-Hsi Hsieh ◽  
Chin-Lin Perng ◽  
Fa-Yauh Lee ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Peptic Ulcer ◽  
Endoscopic Therapy ◽  
Ulcer Bleeding ◽  
Peptic Ulcer Bleeding ◽  
Short Term ◽  
Rebleeding Rate

scholarly journals Endoscopic Cyanoacrylate Injection Treatment for Refractory High-risk Peptic Ulcer Bleeding by Conventional Endoscopic Therapy

2022 ◽  
Author(s):  
Biguang Tuo ◽  
Haijun Mou ◽  
Cheng Zou ◽  
Guoqing Shi ◽  
Sheng Wu ◽  
...  
Keyword(s):  
Peptic Ulcer ◽  
High Risk ◽  
Endoscopic Therapy ◽  
Ulcer Bleeding ◽  
Peptic Ulcer Bleeding ◽  
Intravascular Injection ◽  
Injection Treatment ◽  
Life Threatening ◽  
Rebleeding Rate ◽  
Hemostatic Therapy

Abstract Bleeding is a major and potentially life-threatening complication of peptic ulcer. Despite endoscopic hemostatic therapy advance, conventional endoscopic hemostatic modalities remain refractory for peptic ulcer bleeding with big size, fibrous base or in difficult-to-access anatomical locations. In this study, we attempted to evaluate the efficacy and safety of endoscopic cyanoacrylate injection treatment (ECIT) for refractory high-risk peptic ulcer bleeding by conventional endoscopic therapy. The patients with refractory high-risk peptic ulcer bleeding by conventional endoscopic therapy were carried out ECIT. The data were retrospectively collected. A total of 119 patients accepted ECIT. 74 patients (62.18%) obtained successful intravascular injection and perivascular injection was performed in 45 patients (37.82%). Immediate hemostatic rate for active bleeding achieved 90.91%. Rebleeding rate within 30 days was 12.07%. Overall successful hemostasis rate achieved 87.93%. Immediate hemostatic rate and overall successful hemostasis rate in intravascular injection patients were markedly superior over perivascular injection. Rebleeding rate in intravascular injection patients was markedly lower than that in perivascular injection patients. 11 patients complicated abdominal pain and no other complication occurred. In conclusion, ECIT, especial intravascular injection, was effective and safe, with high successful hemostasis rate for refractory high-risk peptic ulcer bleeding by conventional endoscopic therapy.

scholarly journals Intravenous Pantoprazole as an Adjuvant Therapy following Successful Endoscopic Treatment for Peptic Ulcer Bleeding

2009 ◽  
Vol 23 (4) ◽  
pp. 287-299 ◽  
Author(s):  
Jun Wang ◽  
Kehu Yang ◽  
Bin Ma ◽  
Jinhui Tian ◽  
Yali Liu ◽  
...  
Keyword(s):  
Peptic Ulcer ◽  
Blood Transfusion ◽  
Hospital Stay ◽  
Endoscopic Treatment ◽  
Surgical Intervention ◽  
Weighted Mean Difference ◽  
Ulcer Bleeding ◽  
Peptic Ulcer Bleeding ◽  
Weighted Mean ◽  
Transfusion Requirements

BACKGROUND: Several studies have suggested that proton pump inhibitors are efficacious in preventing rebleeding when administered immediately after endoscopic treatments. However, there are limited clinical outcome data on the use of intravenous pantoprazole.OBJECTIVE: To evaluate the efficacy of intravenous pantoprazole after successful endoscopic treatment for peptic ulcer bleeding using evidence from randomized controlled trials (RCTs).METHODS: The Cochrane Library, MEDLINE, EMBASE and several Chinese databases up to July 2008 were searched. RCTs that compared the relative effectiveness of intravenous pantoprazole with placebo, H2receptor antagonist or other agents for patients with peptic ulcer bleeding who were pretreated with successful endoscopic therapies were retrieved.RESULTS: Five RCTs comprising a total of 821 participants were included in the final meta-analysis. Overall, there were significant differences in ulcer rebleeding (RR 0.31; 95% CI 0.18 to 0.53; pooled rates were 4.7% for pantoprazole and 15.0% for control), surgical intervention (RR 0.28, 95% CI 0.09 to 0.83; pooled rates were 1.4% in pantoprazole group versus 6.5% in control) and total length of hospital stay (weighted mean difference −1.53; 95% CI −1.91 to −1.16), but not on mortality (RR 0.72, 95% CI 0.29 to 1.81; pooled mortality rates were 1.9% for pantoprazole versus 2.8% for control) and blood transfusion requirements (weighted mean difference −0.53; 95% CI for random effects −1.04 to −0.02) when compared with control treatments. A series of subgroup analyses supported the results from the main analysis.CONCLUSIONS: Intravenous administration of pantoprazole after endoscopic therapy for peptic ulcer bleeding reduces rates of ulcer rebleeding, surgical intervention and overall duration of hospital stay, but not mortality and blood transfusion requirements compared with placebo, H2receptor antagonist or somatostatin.

Surgical management of peptic ulcer bleeding by Australian and New Zealand upper gastrointestinal surgeons

2013 ◽  
Vol 83 (3) ◽  
pp. 104-108 ◽  
Author(s):  
Ewen A. Griffiths ◽  
Peter G. Devitt ◽  
Tim Bright ◽  
David I. Watson ◽  
Sarah K. Thompson
Keyword(s):  
Peptic Ulcer ◽  
New Zealand ◽  
Surgical Management ◽  
Ulcer Bleeding ◽  
Peptic Ulcer Bleeding ◽  
Upper Gastrointestinal
Sign in / Sign up

Export Citation Format

Share Document